Ademetionine

Ademetionine

SCHEMBL7810282

C[S+](CCC(N)C(=O)O)CC1OC(n2cnc3c(N)ncnc32)C(O)C1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CARM1 Q86X55 5/20 1.00
AMD1 P17707 4/20 1.00
PCMT1 P22061 3/20 0.87
PRMT5 O14744 3/20 0.87
PRMT1 Q99873 3/20 0.87
NSD3 Q9BZ95 2/20 0.87
PRMT3 O60678 2/20 0.87
PNMT P11086 2/20 0.87
PRMT6 Q96LA8 2/20 0.87
WDR77 Q9BQA1 2/20 0.87
PRMT7 Q9NVM4 2/20 0.87
ADORA3 P0DMS8 1/20 0.87
KDR P35968 1/20 0.87
PRMT8 Q9NR22 1/20 0.87
NNMT P40261 3/20 0.72
DOT1L Q8TEK3 5/20 0.71
NSD2 O96028 3/20 0.71
SETD7 Q8WTS6 3/20 0.71
EHMT2 Q96KQ7 3/20 0.71
TRDMT1 O14717 2/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ademetionine SCHEMBL13033865 1.00 CARM1 (1.00) CARM1AMD1PCMT1PRMT5PRMT1
Ademetionine SCHEMBL600368 1.00 CARM1 (1.00) CARM1AMD1PCMT1PRMT5PRMT1
Ademetionine SCHEMBL66767 1.00 CARM1 (1.00) CARM1AMD1PCMT1PRMT5PRMT1
Ademetionine SCHEMBL2007787 1.00 CARM1 (1.00) CARM1AMD1PCMT1PRMT5PRMT1
Ademetionine SCHEMBL599664 1.00 CARM1 (1.00) CARM1AMD1PCMT1PRMT5PRMT1
Ademetionine SCHEMBL4164615 1.00 CARM1 (1.00) CARM1AMD1PCMT1PRMT5PRMT1
Ademetionine SCHEMBL55479 1.00 CARM1 (1.00) CARM1AMD1PCMT1PRMT5PRMT1
Ademetionine SCHEMBL59293 1.00 CARM1 (1.00) CARM1AMD1PCMT1PRMT5PRMT1
Ademetionine SCHEMBL3202538 1.00 CARM1 (1.00) CARM1AMD1PCMT1PRMT5PRMT1
Ademetionine SCHEMBL9518716 1.00 CARM1 (1.00) CARM1AMD1PCMT1PRMT5PRMT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220153875-A1 ANTIGEN-BINDING MOLECULE CONTAINING ANTIGEN-BINDING DOMAIN OF WHICH BINDING ACTIVITY TO ANTIGEN IS CHANGED DEPENDING ON MTA, AND LIBRARY FOR OBTAINING SAID ANTIGEN-BINDING DOMAIN CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2022-05-19 US disclosed
US-20100150871-A1 Genetically-modified strain of yeast with an increased production and output of s-adenosylmethionine (sam) CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQE (FR) 2010-06-17 US disclosed
US-20090197824-A1 Extended Release Pharmaceutical Formulations of S-Adenosylmethionine METHYLATION SCIENCES INTERNATIONAL SRL (BB) 2009-08-06 US disclosed
US-20090088404-A1 Extended Release Pharmaceutical Formulations of S-Adenosylmethionine METHYLATION SCIENCES INTERNATIONAL SRL (BB) 2009-04-02 US disclosed
US-20080206333-A1 Extended Release Pharmaceutical Formulations of S-Adenosylmethionine METHYLATION SCIENCES INTERNATIONAL SRL (BB) 2008-08-28 US disclosed
US-20080132525-A1 isoforms DNMT1 and DNMT3b2; for example: 2-amino-4-(((2S,3S,4R,5R)-3,4-dihydroxy-5-(6-(phenethylamino)-9H-purin-9-yl)-tetrahydrofuran-2-yl)methylthio)butanoic acid METHYLGENE INC. (CA) 2008-06-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220153875-A1 ANTIGEN-BINDING MOLECULE CONTAINING ANTIGEN-BINDING DOMAIN OF WHICH BINDING ACTIVITY TO ANTIGEN IS CHANGED DEPENDING ON MTA, AND LIBRARY FOR OBTAINING SAID ANTIGEN-BINDING DOMAIN MICA, TNFSF10, HLA-A CARM1 839/4885AMD1 322/4885PCMT1 655/4885
US-20100150871-A1 Genetically-modified strain of yeast with an increased production and output of s-adenosylmethionine (sam) AHCY, MAT2A, MAT1A CARM1 220/4885AMD1 4/4885PCMT1 647/4885
US-20080206333-A1 Extended Release Pharmaceutical Formulations of S-Adenosylmethionine MAT2A, MAT1A, AMD1 CARM1 287/4885AMD1 3/4885PCMT1 340/4885
US-20090197824-A1 Extended Release Pharmaceutical Formulations of S-Adenosylmethionine MAT2A, MAT1A, AMD1 CARM1 287/4885AMD1 3/4885PCMT1 340/4885
US-20080132525-A1 isoforms DNMT1 and DNMT3b2; for example: 2-amino-4-(((2S,3S,4R,5R)-3,4-dihydroxy-5-(6-(phenethylamino)-9H-purin-9-yl)-tetrahydrofuran-2-yl)methylthio)butanoic acid DNMT3B, DNMT1, DNMT3L CARM1 158/4885AMD1 122/4885PCMT1 872/4885
US-20090088404-A1 Extended Release Pharmaceutical Formulations of S-Adenosylmethionine MAT2A, MAT1A, AMD1 CARM1 287/4885AMD1 3/4885PCMT1 340/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.